While the Patented Medicine Prices Review Board (PMPRB) 2007 Budget Impact Analysis (BIA) Guidelines were once considered to be a primary resource for preparation of pharmaceutical BIAs, they no longer reflect current best practices. Recently, thorough review and revision BIA was undertaken by PMPRB staff more closely align them with Canadian requirements international approaches. With new stre...